Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Controlled, Open-Label Parallel Arm Study of Safety, PK and Ammonia Control of RAVICTI® (Glycerol Phenylbutyrate) Oral Liquid and Sodium Phenylbutyrate in Phenylbutyrate Treatment Naïve Patients With Urea Cycle Disorders

NCT03335488 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03335488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03335488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Controlled, Open-Label Parallel Arm Study of Safety, PK and Ammonia Control of RAVICTI® (Glycerol Phenylbutyrate) Oral Liquid and Sodium Phenylbutyrate in Phenylbutyrate Treatment Naïve Patients With Urea Cycle Disorders
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
February 20, 2018
Completion date
December 20, 2022
Enrollment
16 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

urea cycle disorder